Drugs Made In Amer Acqutn Stock Price, News & Analysis
Company Description
Drugs Made In Amer Acqutn (NASDAQ: DMAAR) is a publicly traded company in the Blank Checks sector.
DMAAR stock has declined 24.6% over the past year. Shares last traded at $0.1112.
On a trailing twelve-month basis, Drugs Made In Amer Acqutn reported net income of $5.9M.
This page provides a comprehensive overview of DMAAR stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Drugs Made In Amer Acqutn (DMAAR) stock last traded at $0.1112, down 7.41% from the previous close. Over the past 12 months, the stock has lost 24.6%.
Latest News
SEC Filings
Drugs Made In Amer Acqutn has filed 10 recent SEC filings, including 6 Form 8-K, 2 Form 10-Q, 2 Form SCHEDULE 13G. The most recent filing was submitted on May 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMAAR SEC filings →
Financial Highlights
operating income reached -$2.8M, and net income was $5.9M. The company generated -$539K in operating cash flow. With a current ratio of 0.03, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Drugs Made In Amer Acqutn (DMAAR) currently stands at 16.7 thousand shares, down 70.0% from the previous reporting period. Over the past 12 months, short interest has increased by 100.3%.
Days to Cover History
Days to cover for Drugs Made In Amer Acqutn (DMAAR) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 61.5% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 17.9 days.
DMAAR Company Profile & Sector Positioning
Drugs Made In Amer Acqutn (DMAAR) operates in the Blank Checks sector and is listed on the NASDAQ.